Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hormel Foods Corp (HRL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Hormel Foods CorpTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Hormel Foods Corp vs IDEXX Laboratories, Inc. — how do they compare? Hormel Foods Corp trades at $19.21 (market cap $10.69B), while IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.8× Hormel Foods Corp's market cap, and Hormel Foods Corp pays a 6.02% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and IDEXX Laboratories, Inc. for 46 Days on average.

HRLIDXX
Market Cap
$10.69B$40.43B
Volume
10,041,387692,164
Sector
Consumer StaplesHealth
52-Week High
$26.50$766.68
52-Week Low
$19.42$504.70
Typical Hold Time
99 Days46 Days
Enterprise Value
$12.67B$41.32B
Dividend Yield
6.02%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hormel Foods Corp

Hormel Foods (HRL) trades at $19.23, down 1.64% on the day, with a bearish technical outlook despite recent earnings beats. The company maintains a P/E of 31.32 and P/S of 0.88, with net income margin at 2.82%. Recent $1.06B Brakebush acquisition aims to expand foodservice presence, while dividend consistency remains a key investor focus with 60 consecutive years of increases.

Outlook remains cautious with mixed analyst sentiment (20% buy, 57% hold) and a $24.25 consensus target offering 26% upside. Risks include margin pressure, acquisition integration challenges, and declining dividend growth rates. The stock presents value potential but requires monitoring of operational execution amid competitive pressures.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.

The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HRL
12% Buy88% Sell
Avg holding period · 99 Days
IDXX

No sentiment data available yet.

Top news

Latest headlines on both assets

About Hormel Foods Corp

Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.

Read more on HRL →

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →